1
|
Jonckers THM, Tahri A, Vijgen L, Berke JM, Lachau-Durand S, Stoops B, Snoeys J, Leclercq L, Tambuyzer L, Lin TI, Simmen K, Raboisson P. Discovery of 1-((2R,4aR,6R,7R,7aR)-2-Isopropoxy-2-oxidodihydro-4H,6H-spiro[furo[3,2-d][1,3,2]dioxaphosphinine-7,2'-oxetan]-6-yl)pyrimidine-2,4(1H,3H)-dione (JNJ-54257099), a 3'-5'-Cyclic Phosphate Ester Prodrug of 2'-Deoxy-2'-Spirooxetane Uridine Triphosphate Useful for HCV Inhibition. J Med Chem 2016; 59:5790-8. [PMID: 27181575 DOI: 10.1021/acs.jmedchem.6b00382] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
JNJ-54257099 (9) is a novel cyclic phosphate ester derivative that belongs to the class of 2'-deoxy-2'-spirooxetane uridine nucleotide prodrugs which are known as inhibitors of the HCV NS5B RNA-dependent RNA polymerase (RdRp). In the Huh-7 HCV genotype (GT) 1b replicon-containing cell line 9 is devoid of any anti-HCV activity, an observation attributable to inefficient prodrug metabolism which was found to be CYP3A4-dependent. In contrast, in vitro incubation of 9 in primary human hepatocytes as well as pharmacokinetic evaluation thereof in different preclinical species reveals the formation of substantial levels of 2'-deoxy-2'-spirooxetane uridine triphosphate (8), a potent inhibitor of the HCV NS5B polymerase. Overall, it was found that 9 displays a superior profile compared to its phosphoramidate prodrug analogues (e.g., 4) described previously. Of particular interest is the in vivo dose dependent reduction of HCV RNA observed in HCV infected (GT1a and GT3a) human hepatocyte chimeric mice after 7 days of oral administration of 9.
Collapse
Affiliation(s)
- Tim H M Jonckers
- Janssen Infectious Diseases - Diagnostics BVBA , Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Abdellah Tahri
- Janssen Infectious Diseases - Diagnostics BVBA , Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Leen Vijgen
- Janssen Infectious Diseases - Diagnostics BVBA , Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Jan Martin Berke
- Janssen Infectious Diseases - Diagnostics BVBA , Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Sophie Lachau-Durand
- Janssen Infectious Diseases - Diagnostics BVBA , Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Bart Stoops
- Janssen Infectious Diseases - Diagnostics BVBA , Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Jan Snoeys
- Janssen Infectious Diseases - Diagnostics BVBA , Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Laurent Leclercq
- Janssen Infectious Diseases - Diagnostics BVBA , Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Lotke Tambuyzer
- Janssen Infectious Diseases - Diagnostics BVBA , Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Tse-I Lin
- Janssen Infectious Diseases - Diagnostics BVBA , Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Kenny Simmen
- Janssen Infectious Diseases - Diagnostics BVBA , Turnhoutseweg 30, 2340 Beerse, Belgium
| | - Pierre Raboisson
- Janssen Infectious Diseases - Diagnostics BVBA , Turnhoutseweg 30, 2340 Beerse, Belgium
| |
Collapse
|